Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies

Objectives: To determine the validity, reliability, and responsiveness of a new overall disability sum score in immune mediated polyneuropathies. Methods: Three impairment measures (MRC sum score, sensory sum score, grip strength (Vigorimeter)) and three disability scales (an overall disability sum score (ODSS), Hughes' functional scale (f score), Rankin scale) were assessed in a cross sectional group of 113 clinically stable patients (83 with Guillain–Barré syndrome, 22 with chronic inflammatory demyelinating polyneuropathy (CIDP), eight with a gammopathy related polyneuropathy). The ODSS was also used serially in 20 patients with recently diagnosed Guillain–Barré syndrome (n = 7) or CIDP (n = 13) and changing clinical conditions. Multiple regression studies were performed to compare the impact of impairment disturbances (independent variables) on the various disability scales (dependent variable). Results: Moderate to good construct validity (stable group: Spearman's rank test (absolute values), r = 0.41–0.79; longitudinal group: multiple correlation coefficient, R = 0.69–0.89; p < 0.006 for all associations) and reliability (intraclass correlation coefficient, R = 0.90–0.95; p < 0.0001) were demonstrated for the ODSS. Its SRM values were high (> 0.8), indicating good responsiveness. Impairment measures accounted for a higher variance proportion of the ODSS compared with the f score and Rankin (R = 0.64 v 0.56 and 0.45, respectively). Conclusions: All clinimetric requirements were met by the overall (arm and leg) disability sum score in immune mediated polyneuropathies. Its use is therefore suggested in evaluating immune mediated polyneuropathies.

[1]  K. Toyka,et al.  Assessing grip strength in healthy individuals and patients with immune‐mediated polyneuropathies , 2000, Muscle & nerve.

[2]  P. V. van Doorn,et al.  Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies , 2000, Neurology.

[3]  P. Schmitz,et al.  Fatigue in immune-mediated polyneuropathies , 1999, Neurology.

[4]  P. Schmitz,et al.  Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome , 1999, Neurology.

[5]  J. Gabriel,et al.  Paraproteinaemic Neuropathies , 1999, Bailliere's clinical neurology.

[6]  B. Sharrack,et al.  Scale development and Guy’s Neurological Disability Scale , 1999, Journal of Neurology.

[7]  R. D. de Haan,et al.  Impact of neurologic signs and symptoms on functional status in peripheral neuropathies , 1999, Neurology.

[8]  H. Hartung,et al.  Guillain-Barré syndrome, CIDP and other chronic immune-mediated neuropathies. , 1998, Current opinion in neurology.

[9]  W. Hacke,et al.  Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome , 1997 .

[10]  A. Thompson,et al.  Evaluating neurological outcome measures : the bare essentials , 2022 .

[11]  J. Katz,et al.  Measuring relevant change: an emerging challenge in rheumatologic clinical trials. , 1995, Arthritis and rheumatism.

[12]  M H Liang,et al.  Evaluating measurement responsiveness. , 1995, The Journal of rheumatology.

[13]  G. Bydder,et al.  Brain swelling in first hour after coronary artery bypass surgery , 1993, The Lancet.

[14]  R. Hughes,et al.  Reasons for Persistent Disability in Guillain-Barré Syndrome , 1993 .

[15]  P. Schmitz,et al.  A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. , 1992, The New England journal of medicine.

[16]  M. Feinleib,et al.  Statistical Models for Longitudinal Studies of Health , 1992 .

[17]  P. Schmitz,et al.  Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain‐Barré syndrome , 1991, Muscle & nerve.

[18]  Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) , 1991, Neurology.

[19]  M. Liang,et al.  Comparisons of Five Health Status Instruments for Orthopedic Evaluation , 1990, Medical care.

[20]  B. Ford International Classification of Impairments, Disabilities and Handicaps , 1984, Releve epidemiologique hebdomadaire.

[21]  M. Matthay,et al.  Guillain-Barré syndrome: psychosocial aspects of management. , 1983, Psychosomatics.

[22]  R. Hughes,et al.  CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY , 1978, The Lancet.

[23]  D. Cornblath,et al.  Assessment of current diagnostic criteria for Guillain‐Barré syndrome , 1990, Annals of neurology.

[24]  Frank E. Harrell,et al.  The restricted cubic spline hazard model , 1990 .

[25]  R. Bloch,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.

[26]  G. Guyatt,et al.  Measuring change over time: assessing the usefulness of evaluative instruments. , 1987, Journal of chronic diseases.

[27]  B. Ford International classification of impairments, disabilities and handicaps. , 1984, The Medical journal of Australia.